Sodium ion sensitive digestive tract submucosal injection filler and application thereof

By injecting a sodium-sensitive submucosal filler into the digestive tract, gelling gum reacts with sodium ions to form a gel, solving the problem of submucosal injections being unable to maintain elevation and hemostasis for a long time. This achieves the effects of long-term mucosal elevation and rapid hemostasis, and is suitable for digestive tract surgery and medical aesthetic applications.

CN121371300APending Publication Date: 2026-01-23HANGZHOU ANJIE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511206912.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-10-21
Filing Date
2025-08-27
Publication Date
2026-01-23

AI Technical Summary

Technical Problem

Existing submucosal injection solutions are difficult to maintain sufficient mucosal elevation time during endoscopic mucosal dissection and lack hemostatic effect, which can easily lead to bleeding complications.

Method used

A sodium-sensitive submucosal injection filler is used in the digestive tract. The gelling agent reacts with sodium ions in human tissue to form a gel, providing a good mucosal elevation effect and interacting with blood to quickly coagulate and stop bleeding.

Benefits of technology

It achieves a long-lasting submucosal elevation and rapid hemostasis, reducing bleeding complications during mucosal dissection. It is suitable for submucosal injection in the digestive tract, wound protection, and cosmetic skin and soft tissue filling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121371300A_ABST
    Figure CN121371300A_ABST
Patent Text Reader

Abstract

The invention provides a sodium ion-sensitive digestive tract submucosa injection filler and application thereof. The filler comprises a calcium ion complexing cosolvent, gellan gum, a thickening agent, an osmotic pressure regulator and a pH regulator. By utilizing the characteristic that gellan gum and sodium ions are combined to form gel, the tissue filling material is prepared, the tissue filling material reacts with sodium ions in tissue fluid to form gel after being injected into human tissues, the effects of filling and forming bulges are achieved, and auxiliary substances are specifically added to form a stable and effective filling agent without damage to the body.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to a sodium ion-sensitive submucosal injection filler for the digestive tract and its application. Background Technology

[0002] Endoscopic gastric mucosal resection and gastric mucosal dissection are minimally invasive surgeries for the removal of early-stage gastric cancer and benign gastric tumors. They not only achieve radical cure of early-stage gastric cancer but also offer advantages such as minimal trauma and minimal impact on patient quality of life, gradually replacing some traditional surgical procedures. Minimally invasive surgeries for the removal of early-stage esophageal and colonic cancers and benign tumors have also replaced some traditional surgical procedures. Endoscopic mucosal dissection requires good endoscopic technique, but serious complications such as bleeding and perforation can still occur intraoperatively and postoperatively. Therefore, how to avoid or reduce intraoperative complications during endoscopic mucosal dissection is an important issue that urgently needs to be addressed. To avoid intraoperative bleeding, providing a good surgical field is crucial during endoscopic mucosal dissection; to avoid perforation, sufficient operating space in the submucosal layer is also essential; both of these can be achieved by injecting appropriate and sufficient submucosal injection fluid. During the resection process, the submucosal injection can maintain the elevation for a certain period of time, lifting the diseased mucosa and forming a protective submucosal fluid pad, which separates the mucosal layer from the muscle layer. This can avoid damage to the muscle layer and the tissue below, and prevent complications such as perforation.

[0003] Currently used submucosal injection solutions include physiological saline, hypertonic saline, glucose, glycerol fructose, sodium hyaluronate of varying concentrations, hydroxymethylcellulose, and sodium alginate. Physiological saline is the most commonly used submucosal injection solution; it is an isotonic solution, but its disadvantage is that it is rapidly absorbed by surrounding tissues, making it difficult to create adequate mucosal elevation and maintain the ideal elevation height during resection. Generally, hypertonic solutions can elevate the lesion tissue higher than physiological saline. Glycerol fructose, a hypertonic solution composed of 10% glycerol and 5% fructose, provides a higher mucosal elevation height and longer duration when used in the human colon than physiological saline; however, due to its high osmotic pressure, it can cause some damage to the mucosal tissue. Hyaluronic acid, a viscoelastic biopolysaccharide found in connective tissue, is a component of the matrix for cell growth and tissue structure formation. It has high viscosity and water-retention capacity, is not an antigen of the human body, and is completely non-toxic. Based on current literature, hyaluronic acid provides the longest duration of submucosal water pad formation. Although these products have a certain tumescent effect, the problem of insufficient tumescent effect requiring repeated injections still exists in clinical applications. Furthermore, bleeding complications exist during ESD procedures, and currently used submucosal fillers do not have hemostatic or coagulation properties. Summary of the Invention

[0004] The purpose of this invention is to address the aforementioned problems by providing a sodium-sensitive submucosal injection filler for the digestive tract. When injected into the tissue, the dominant sodium ions in the tissue fluid bind with the gellan gum in the filler (other ions in the body fluid also participate in the binding, but primarily sodium ions, which have the highest content in the body fluid), forming a non-flowing gel. This avoids the fluidity problem of currently used submucosal injection solutions and provides a good swelling effect. Furthermore, the interaction between the filler and wound exudate and blood causes the blood to coagulate rapidly, achieving rapid hemostasis and clotting.

[0005] Another object of the present invention is to provide the application of a sodium-sensitive submucosal injectable filler in the treatment and protection of damaged gastrointestinal mucosa, as well as its application in the filling of soft tissues in cosmetic medicine.

[0006] Another object of the present invention is to provide the application of a sodium ion-sensitive submucosal injection filler in hemostasis and endovascular embolization.

[0007] The filler of the present invention can also be prepared into a highly thixotropic gel by adding physiological concentrations of sodium chloride, which can be used for submucosal filling, wound protection, medical aesthetic skin and soft tissue filling, and radiation therapy protection.

[0008] To achieve the above objectives, the present invention adopts the following technical solutions:

[0009] A submucosal injection filler for the digestive tract includes a calcium ion complexing solubilizer, gellan gum, a thickener, an osmotic pressure regulator, and a pH regulator.

[0010] Furthermore, the calcium ion complexing co-solvent is one or more of trisodium phosphate, sodium citrate, sodium hexametaphosphate, sodium pyrophosphate, and sodium EDTA.

[0011] Furthermore, the gellan gum is one or both of low-acyl gellan gum and non-acyl gellan gum.

[0012] Furthermore, the thickener is one or more of alginate, collagen, recombinant human collagen, gelatin, carboxymethyl chitosan, and sodium hyaluronate.

[0013] Furthermore, the osmotic pressure regulator is one or more of glycerol, glucose, mannitol, sorbitol, propylene glycol, and PEG.

[0014] Furthermore, the pH adjusters mentioned are hydrochloric acid, sodium hydroxide, and potassium hydroxide.

[0015] Furthermore, the mass concentration of the calcium ion complexing agent is 0.02%-0.2%.

[0016] Furthermore, the mass concentration of gellan gum is 0.2%-2.0%.

[0017] Furthermore, the thickener solution contains 0.1%-5% by weight.

[0018] Furthermore, the filler of the present invention can also be prepared into a highly thixotropic gel by adding physiological concentrations of sodium chloride, which can be used in submucosal filling, wound protection, medical aesthetic skin and soft tissue filling, and radiation therapy protection.

[0019] Furthermore, the filler of the present invention can also be combined with active ingredients such as drugs and growth factors to form a drug sustained-release formulation, providing a drug sustained-release effect.

[0020] The filler of this invention is prepared by first adding the complexing co-solvent and gellan gum to deionized water and stirring to disperse them evenly in the deionized water, and then heating to 70℃-90℃ and stirring to dissolve.

[0021] The present invention also provides the application of the above-mentioned submucosal injection filler in the preparation of drugs or medical devices for gastric mucosal dissection, esophageal mucosal dissection, intestinal mucosal dissection and hemorrhoid wound treatment, as well as its application in the preparation of drugs for submucosal injection in the digestive tract for use in mucosal dissection, esophageal mucosal dissection and intestinal mucosal dissection.

[0022] Furthermore, the submucosal injection filler of the digestive tract is injected beneath the mucosa to separate the mucosal layer and the muscle layer.

[0023] Furthermore, the filler of the present invention can also be used in the preparation of filler formulations for medical aesthetic skin soft tissue.

[0024] Furthermore, the filler of the present invention can also be used as a colloidal liquid in wound care adhesives.

[0025] Furthermore, the filler of the present invention is used in the preparation of wound hemostasis and endovascular embolization preparations or medical devices.

[0026] The advantages of this invention are:

[0027] The gellan gum used in this invention is the only biomaterial capable of forming a gel with sodium ions at physiological saline concentrations. Other clinically used fillers, such as sodium alginate, pectin, sodium hyaluronate, hydroxyethyl starch, and cellulose, do not react with sodium ions to form a gel. Sodium ions are the main monovalent cation in human body fluids. This invention utilizes the gel-forming property of gellan gum to prepare a tissue filler material. After injection into human tissue, it reacts with sodium ions in the tissue fluid to form a gel, thus filling and shaping a raised area.

[0028] Under physiological conditions, the sodium ion concentration in human tissue fluid is 145.1 mEq / L (equivalent to the ion content of 0.9% sodium chloride saline). Gellan gum is sodium ion sensitive and can combine with sodium to form a gel. Monovalent sodium ions in tissue fluid or blood complex with carbonyl groups on the gellan gum polymer chains, forming stable double helix interchain hydrogen bonds. Each pair of double helixes aggregates in opposite directions, forming a three-dimensional gel network, reducing its fluidity. Therefore, it can maintain its position at the injection site for a long time, avoiding the need for repeated injections during ESD surgery. The injectable filler of this invention can also be used in conjunction with other digestive tract protective gels to effectively protect the wound after surgery.

[0029] The filler of this invention interacts with blood, causing rapid blood coagulation and thus achieving hemostasis at the wound site. Human plasma contains 153.2 mEq / L of sodium ions. The formulation of this invention interacts with sodium ions in the blood, causing instantaneous blood coagulation, thereby exhibiting excellent hemostatic and coagulation effects. It is also the product that causes the fastest blood coagulation, and it can achieve instantaneous blood coagulation without relying on clotting factors in the blood. This characteristic is effective for both patients with normal and abnormal coagulation functions. Furthermore, this filler has a hemostatic effect, which can help stop bleeding complications during ESD procedures, reducing bleeding complications. Currently used clinical fillers do not have hemostatic properties; therefore, the filler of this invention also has hemostatic properties. Additionally, the filler of this invention, when interacting with blood to form a gel, can also be used for the treatment of endovascular embolization.

[0030] Because the injectable filler of this invention is sensitive to sodium ions, the osmotic pressure regulator used is a non-ionic substance, such as glycerol, glucose, mannitol, sorbitol, propylene glycol, PEG, etc. Adjusting the osmotic pressure to isotonic avoids the damaging effects of hypotonic solutions on tissue cells.

[0031] The gellan gum used in the injection filler of the present invention cannot be completely dissolved in deionized water in the presence of divalent cation calcium ions because calcium ions inhibit the dissolution of gellan gum. Therefore, calcium ion complexing solubilizer needs to be added during the preparation process to complex the calcium ions in the solution, and the solution needs to be completely dissolved to form a stable solution when heating is required.

[0032] In addition, the solid gel formed by the injection filler of the present invention, which is rapidly shaken to break the gel structure into a flowing state and then returns to a solid state after being left to stand still, has the characteristics of a self-healing gel. Therefore, as a covering and protective material for digestive tract wounds, its structure can adapt to changes in the peristaltic morphology of the gastrointestinal tract. Attached Figure Description

[0033] Figure 1These are photographs of the gel formed after adding physiological saline to the injectable fillers prepared in Examples 1-5.

[0034] Figure 2 yes Figure 1 Image showing the injection of filler into a 10ml glass vial after the gel was shaken and broken down, followed by aspiration of the filler into the syringe and allowing it to stand for 2 minutes.

[0035] Figure 3 These are photographs of the gel formed after the injectable fillers prepared in Examples 1-5 were added to chicken plasma.

[0036] Figure 4 Photographs of the gel formed after adding chicken blood to the injectable fillers prepared in Examples 1-5.

[0037] In the above figures, from left to right, they represent Examples 1-5. Detailed Implementation

[0038] Unless otherwise specified, all chemicals used in the embodiments of this invention are common chemicals that can be purchased on the market.

[0039] Example 1

[0040] 5 grams of low-acyl gellan gum

[0041] 2 sodium citrate 0.5 g

[0042] 3 Mannitol 50.7g

[0043] 4 Sodium alginate 5g

[0044] First, 5 grams of low-acyl gellan gum and 0.5 grams of sodium citrate are evenly dispersed in 1000 ml of deionized water. Then, the mixture is heated to 70℃-90℃ and stirred until completely dissolved. 50.7 grams of mannitol and 5 grams of sodium alginate are added and stirred until completely dissolved. The pH is adjusted to 7.5 using 1 mol sodium hydroxide. Then, the volume is adjusted to 1000 ml by adding evaporated water. The mixture is packaged in 10 ml bottles and sterilized by high-temperature steam to obtain the injectable filler.

[0045] Example 2

[0046] 10g of low-acyl gellan gum

[0047] 2 sodium citrate 0.5 g

[0048] 3 Mannitol 50.7g

[0049] 4 carboxymethyl chitosan 5 grams

[0050] First, 10 grams of low-acyl gellan gum and 0.5 grams of sodium citrate are evenly dispersed in 1000 ml of deionized water. Then, the mixture is heated to 70℃-90℃ and stirred until completely dissolved. 50.7 grams of mannitol and 5 grams of carboxymethyl chitosan are added and stirred until completely dissolved. The pH is adjusted to 7.5 using 1 mol sodium hydroxide. Then, the evaporated water is added to bring the volume to 1000 ml. The mixture is packaged in 10 ml bottles and sterilized by high-temperature steam to obtain the injectable filler.

[0051] Example 3

[0052] 3 grams of acyl-free gellan gum

[0053] 0.2 g sodium citrate

[0054] 3 Mannitol 50.7g

[0055] 3 Collagen 2 grams

[0056] First, 3 grams of low-acyl gellan gum and 0.2 grams of sodium citrate are evenly dispersed in 1000 ml of deionized water. Then, the mixture is heated to 70℃-90℃ and stirred until completely dissolved. 50.7 grams of mannitol and 2 grams of collagen are added and stirred until completely dissolved. The pH is adjusted to 7.5 using 1 mol sodium hydroxide. Then, the volume is adjusted to 1000 ml by adding evaporated water. Each vial is packaged in 10 ml bottles and sterilized by high-temperature steam to obtain the injectable filler.

[0057] Example 4

[0058] 5 grams of low-acyl gellan gum

[0059] 2 grams of trisodium 2-phosphate

[0060] 3 Mannitol 50.7g

[0061] 4. Potassium alginate 15g

[0062] First, 5 grams of low-acyl gellan gum and 2 grams of trisodium phosphate are evenly dispersed in 1000 ml of deionized water. Then, the mixture is heated to 70℃-90℃ and stirred until completely dissolved. 50.7 grams of mannitol and 15 grams of potassium alginate are added and stirred until completely dissolved. The pH is adjusted to 7.5 using 1 mol sodium hydroxide. Then, the evaporated water is added to bring the volume to 1000 ml. The mixture is packaged in 10 ml bottles and sterilized by high-temperature steam to obtain the injectable filler.

[0063] Example 5

[0064] 15g of low-acyl gellan gum

[0065] 2 sodium citrate 0.5 g

[0066] 3 glucose 50 grams

[0067] 4 Sodium alginate 5g

[0068] First, 15 grams of low-acyl gellan gum and 0.5 grams of sodium citrate are evenly dispersed in 1000 ml of deionized water. Then, the mixture is heated to 70℃-90℃ and stirred until completely dissolved. 50 grams of mannitol and 5 grams of sodium alginate are added and stirred until completely dissolved. The pH is adjusted to 7.5 using 1 mol sodium hydroxide. Then, the volume is adjusted to 1000 ml by adding evaporated water. Each vial is packaged in 10 ml bottles and sterilized by high-temperature steam to obtain the injectable filler.

[0069] Evaluation of Experimental Results

[0070] The products described in the above embodiments are used directly for testing.

[0071] 1. Saline gel test

[0072] The injectable fillers prepared in Examples 1-5 were mixed with 0.9% physiological saline at a 1:1 (v:v) ratio. 20 ml of the injectable filler was added to 20 ml of physiological saline, and the gelation process was observed. All injectable fillers prepared in Examples 1-5 formed gels (see...). Figure 1 From left to right, these are Examples 1-5. Additionally, a gel was rapidly shaken to disrupt its structure into a flowing state, then allowed to stand before reverting to a solid state. In this experiment, 5 ml of the formed gel was drawn into a syringe through a needle and injected into a 10 ml glass bottle. After standing for 2 minutes, it reverted to a non-flowing gel (see...). Figure 2 (From left to right, these are Examples 1-5). This shows that the product of the present invention undergoes a gelation reaction under physiological saline conditions to form a solid gel, and has the properties of a self-healing gel.

[0073] 2. Plasma coagulation test

[0074] The injectable fillers prepared in Examples 1-5 were mixed with fresh chicken plasma (prepared by centrifuging fresh chicken blood with sodium citrate anticoagulation to remove cell components) at a ratio of 2:1 (v:v). 4 ml of the injectable filler was added to 2 ml of chicken plasma and mixed, and the gelation process was observed. All injectable fillers prepared in Examples 1-5 formed gels (see...). Figure 3 (From left to right, these are Examples 1-5). Experiments have shown that the formulation of the present invention can induce plasma coagulation without the involvement of coagulation factors.

[0075] 3. Blood coagulation test

[0076] The injectable fillers prepared in Examples 1-5 were mixed with fresh chicken blood anticoagulated with sodium citrate at a ratio of 2:1 (v:v). 4 ml of the injectable filler was added to 2 ml of chicken blood, and the gelation process was observed. All injectable fillers prepared in Examples 1-5 formed gels (see...). Figure 4(From left to right: Examples 1-5). Further experiments demonstrated that the formulation of this invention can induce blood clotting without the involvement of clotting factors. Therefore, this property has a blood-clotting effect on patients with both normal and abnormal clotting functions, and it should be the most potent hemostatic and coagulation-promoting agent currently available.

[0077] 4 Safety Research Trials

[0078] The injectable fillers prepared in Examples 1-5 were subjected to the following biological tests.

[0079] 1) Oral mucosal irritation: The test solution was prepared by adding physiological saline at a ratio of 0.2 g / ml. A cotton ball with a diameter no greater than 5 mm was soaked in the test solution and placed in the cheek pouch of three golden hamsters. Each contact lasted at least 5 minutes, once a day for a total of 4 times. The cheek pouch was visually observed 24 hours after the last contact. The hamsters were euthanized painlessly, and tissue samples from representative areas of the cheek pouch were fixed in 4% formaldehyde solution, prepared into tissue sections, and then subjected to histological evaluation. The results showed that the irritation index was 0 in all samples, indicating no oral mucosal irritation.

[0080] 2) Cytotoxicity: The test solution was prepared by adding cell culture medium at a ratio of 0.2 g / ml. Then, the cytotoxicity test was performed using the MTT assay as specified in the national standard GB / T16886.5 Biological Evaluation of Medical Devices. The results of the cytotoxicity test showed that the cell proliferation rate was in the range of 85%-105%, and there was no cytotoxicity.

[0081] 3) Sensitization test: The test solution was prepared by adding physiological saline at a ratio of 0.2 g / ml. Then, skin sensitization tests were performed according to the methods specified in the national standard GB / T16886.10 Biological Evaluation of Medical Devices, and no sensitization effect was observed.

[0082] 5. Mucosal Elevation Effect Test

[0083] 1) Experimental materials:

[0084] (1) Three fresh detached pig stomachs were purchased from the supermarket and stored in a refrigerator at 4°C when needed. The experimental time was no more than 12 hours after the pig slaughter time.

[0085] (2) Experimental table, syringe, timer, pins, thread, camera, ruler, white foam board. 23G and 25G (Gauge, abbreviated as G) injection needles.

[0086] 2) Test methods

[0087] The pig stomach was fixed to a square foam board using pins. Six groups of solutions (1 ml each) – the injection filler from Examples 1-5 and physiological saline (control) – were injected submucosally. An edema immediately formed under the pig stomach mucosa. The height of each edema (0 min) was measured using a ruler and thread, and photographs were taken perpendicular to the plane of the stomach using a digital camera to accurately record the height. The stomach was then immersed in physiological saline, and the edema height was measured again at the same location after 15, 30, and 60 min, with photographs taken simultaneously. Each submucosal injection experiment was independently repeated three times. The results showed that the present invention has a good mucosal edema effect. The experimental results are shown in Table 1.

[0088] Table 1: Experimental Results

[0089]

[0090] The specific embodiments described herein are merely illustrative examples of the spirit of the invention. Those skilled in the art to which this invention pertains may make various modifications or additions to the described specific embodiments or use similar methods to substitute them, without departing from the spirit of the invention.

Claims

1. A sodium-sensitive submucosal injection filler for the digestive tract, characterized in that, The filler includes calcium ion complexing cosolvent, gellan gum, osmotic pressure regulator, pH regulator, and thickener.

2. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The calcium ion complexing co-solvent is one or more of the following: trisodium phosphate, sodium citrate, sodium hexametaphosphate, sodium pyrophosphate, and sodium EDTA.

3. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The gellan gum is one or both of low-acyl gellan gum and non-acyl gellan gum.

4. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The thickener is one or more of alginate, collagen, recombinant human collagen, gelatin, carboxymethyl chitosan, and sodium hyaluronate.

5. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The osmotic pressure regulator is one or more of glycerol, glucose, mannitol, sorbitol, propylene glycol, and PEG.

6. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The mass concentration of the calcium ion complexing co-solvent is 0.02%-0.2%.

7. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The mass concentration of gellan gum is 0.2%-2.0%.

8. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, The thickener solution contains 0.1%-5% by weight.

9. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, It also includes sodium chloride, with the concentration of sodium chloride being the physiological concentration.

10. The sodium-sensitive submucosal injection filler for the digestive tract according to claim 1, characterized in that, It also includes drugs and growth factors.

11. The use of a sodium-sensitive submucosal injection filler for digestive tract as described in any one of claims 1-10 in the preparation of esophageal mucosal stripping, gastric mucosal stripping, intestinal mucosal stripping, anorectal surgical wounds, peptic ulcer drugs, or medical devices.

12. The use of a sodium-sensitive submucosal injectable filler for the digestive tract as described in any one of claims 1-10 in the preparation of filler formulations for skin and soft tissue.

13. The application of the sodium ion-sensitive submucosal injection filler of the digestive tract according to claim 11 as a colloidal solution, wound hemostasis agent, and intravascular embolization agent in the preparation of wound protective adhesive.